Sign In
Buy ACON
$2.25
+0.230 (+11.39%)
At Close: Jul 31, 2026
Aclarion Publishes CEO Shareholder Letter Highlighting Progress for First Half of 2026
07:03am, Wednesday, 29'th Jul 2026
PR Audio: Broomfield, CO, July 29, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – Aclarion, Inc.
Aclarion Publishes CEO Shareholder Letter Highlighting Progress for First Half of 2026
07:00am, Wednesday, 29'th Jul 2026
141% year-over-year scan volume growth in first half of 2026 Reimbursement momentum in the U.K. translating into consistent scan volume growth Launched Market Access Program in partnership with PRIA H
Aclarion Announces Presentation of Two Abstracts Highlighting Nociscan's Growing Role in Real-World Clinical Practice
07:04am, Tuesday, 21'st Jul 2026
PR Audio: BROOMFIELD, Colo., July 21, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – Aclarion, Inc.
Aclarion Announces Presentation of Two Abstracts Highlighting Nociscan's Growing Role in Real-World Clinical Practice
07:00am, Tuesday, 21'st Jul 2026
Abstracts presented at American Society of Pain & Neuroscience (ASPN) annual meeting across surgical decision support and basivertebral nerve ablation Early findings from real-world evidence study dem
Aclarion Announces Texas Spine Care Center as New CLARITY Site
07:01am, Tuesday, 07'th Jul 2026
PR Audio: BROOMFIELD, Colo., July 07, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – Aclarion, Inc.
Aclarion Announces Texas Spine Care Center as New CLARITY Site
07:00am, Tuesday, 07'th Jul 2026
Texas Spine Care Center is a high-volume orthopedic spine practice with a philosophy of understanding the exact source of a patient's pain before recommending treatment CLARITY is a prospective, rando
Aclarion to Present at the Planet MicroCap Las Vegas Powered by MicroCapClub
07:00am, Wednesday, 10'th Jun 2026
BROOMFIELD, Colo., June 10, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company leveraging biomarke
Aclarion Partners with PRIA Healthcare to Advance Reimbursement and Commercial Adoption of Its AI-Powered Nociscan Platform
07:00am, Tuesday, 09'th Jun 2026
Partnership supports reimbursement strategy and U.S. commercial expansion for Aclarion's AI-driven platform for chronic low back pain.
Aclarion Partners with PRIA Healthcare to Advance Reimbursement and Commercial Adoption of Its AI-Powered Nociscan Platform
07:00am, Tuesday, 09'th Jun 2026
Partnership supports reimbursement strategy and U.S. commercial expansion for Aclarion's AI-driven platform for chronic low back pain. Program aims to follow successful reimbursement wins in the UK th
Aclarion Rejects Echo Lake Capital's Unsolicited Acquisition Proposal
07:06am, Monday, 08'th Jun 2026
PR Audio: BROOMFIELD, Colo., June 8, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – Aclarion, Inc.
Aclarion Rejects Echo Lake Capital's Unsolicited Acquisition Proposal
07:05am, Monday, 08'th Jun 2026
BROOMFIELD, Colo., June 08, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc. , (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging b
Aclarion Stockholders Approve All Proposals at 2026 Annual Meeting
07:02am, Monday, 08'th Jun 2026
BROOMFIELD, Colo., June 8, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial
Aclarion Stockholders Approve All Proposals at 2026 Annual Meeting
07:00am, Monday, 08'th Jun 2026
BROOMFIELD, Colo., June 08, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging bi
Aclarion Adds Institute of Neuro Innovation to Support Nociscan Growth and Real-World Evidence Generation
06:00am, Wednesday, 03'rd Jun 2026
Broomfield, CO, June 3, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-st
Aclarion Adds Institute of Neuro Innovation to Support Nociscan Growth and Real-World Evidence Generation
06:00am, Wednesday, 03'rd Jun 2026
Expands availability of Nociscan in the greater Los Angeles area with leading neuroscience group Adds to growing body of real-world evidence with study comparing chemical biomarker data from Nociscan
